As of 2024, Moderna net worth remains a focal point of interest, especially given the company’s key products, including Spikevax.
In this article, we’ll explore Moderna net worth, its major financial drivers, and how its products influence overall performance. Let’s dive into the details provided by Ando Money.
Quick Facts
| FACT | DETAIL |
|---|---|
| Name | Moderna |
| Full Name | Moderna, Inc. |
| Website | modernatx.com |
| Industry | Biotechnology |
| Traded as | NASDAQ: MRNA |
| ISIN | US60770K1079 |
| Founded | 2010 |
| Founders | Noubar Afeyan, Robert S. Langer, Derrick Rossi, Kenneth R. Chien |
| Country/Territory | United States |
| Headquarters | Cambridge, Massachusetts, U.S. |
| Chief Executive Officer | Stéphane Bancel |
| Number of Employees | 4,000 |
| Market Cap | $22.62 billion (October 2024) |
| Total Assets | $15.68 billion (June 30, 2024) |
| Total Equity | $11.71 billion (June 30, 2024) |
| Revenue | $241 million (Q2 2024) |
| Net Income | $(1.3) billion (Q2 2024) |
What is the Net Worth/Market Cap of Moderna in 2024?
In October 2024, Moderna has a market cap of $22.62 billion, placing it among the most notable biotech companies globally.
While its market value has been impacted by the competitive vaccine landscape, it still maintains strong financial positioning compared to other biotech firms.
As we look at companies in a similar space, it’s worth noting how Moderna’s performance stacks up against competitors. Below are some related entities in the same sector:
- Pfizer
- BioNTech
- Gilead Sciences
- Johnson & Johnson
- AstraZeneca
- Sanofi
- Merck
- GlaxoSmithKline
- Novavax
- Regeneron
For more insights into the world’s wealthiest companies, check out this resource on financial giants.
Moderna Financial Performance Overview
Revenue Breakdown in 2024
Moderna’s revenue in Q2 2024 was $241 million, a decrease from the previous year.
The dip was largely due to shrinking demand for COVID-19 vaccines, marking a shift from pandemic-driven sales to more seasonal revenue.
As the COVID-19 vaccine market becomes more competitive, Moderna’s sales have been affected, though demand is expected to rise later in the year.
Key Products Driving Moderna’s Revenue
Spikevax remains the top product for Moderna, contributing $184 million to the Q2 2024 revenue.
The U.S. accounted for the majority of these sales, followed by international markets.
Additionally, the launch of the mRESVIA vaccine, targeting RSV, is expected to contribute significantly to the company’s revenue in the coming quarters.
Geographic Revenue Distribution
Most of Moderna’s revenue in Q2 2024 came from the U.S., with $162 million in sales, while international sales brought in $22 million.
Moderna’s presence in the European Union is shrinking, with the company predicting low sales in this region for the remainder of 2024.
However, strong demand from the Rest of World markets is helping to offset these challenges.
Operational Costs and Their Impact on Revenue
Moderna’s cost of sales in Q2 2024 was $115 million, comprising third-party royalties, inventory write-downs, and unutilized manufacturing capacity.
Despite these costs, the company managed to lower its overall operating expenses.
This reduction aligns with a strategic focus on efficiency, as the cost of sales decreased by 84% year-on-year.
Research and Development Investment and Future Financial Growth
Moderna invested heavily in R&D, with $1.2 billion spent in Q2 2024.
These funds are driving the development of the next generation of vaccines, including combination vaccines for flu and COVID-19.
Although these investments impact current earnings, they set the stage for future revenue growth.
Strategic Partnerships and Their Financial Contribution
Partnerships continue to play a key role in Moderna’s strategy.
Collaborations, such as the one with Mitsubishi Tanabe Pharma, are crucial for expanding market access.
These alliances are expected to generate additional revenue as new products are launched.
Competitive Landscape and Its Effect on Revenue
The biotech landscape has become increasingly competitive. Companies like Pfizer and BioNTech continue to be formidable competitors.
This competitive pressure is reflected in Moderna’s shrinking revenue, especially in international markets, where rivals are gaining ground.
Regulatory Approvals and Market Access Influence on Revenue
Regulatory milestones, such as the FDA’s approval of mRESVIA in May 2024, have allowed Moderna to expand its portfolio.
Market access in regions like the U.S. and the EU is crucial to increasing sales of both COVID-19 and RSV vaccines, impacting future revenue positively.
Impact of Seasonal Vaccine Demand on Financial Performance
The seasonality of vaccine demand, particularly for COVID-19 and RSV, has created fluctuations in Moderna’s revenue.
With the bulk of sales expected in the fall and winter, Moderna is well-positioned to capture a larger share of the market during peak vaccine season.
FAQs about Moderna
What are Moderna’s key products in 2024?
Its leading products in 2024 include Spikevax (COVID-19 vaccine) and mRESVIA (RSV vaccine). These products are critical drivers of its revenue.
How much revenue did Moderna generate in Q2 2024?
In Q2 2024, Moderna reported $241 million in revenue, a decrease from the same period in 2023 due to lower COVID-19 vaccine demand.
What is Moderna’s approach to research and development?
It invested $1.2 billion in research and development in Q2 2024, focusing on vaccines and therapeutics, including next-generation mRNA technology.
Where is Moderna headquartered?
It is headquartered in Cambridge, Massachusetts, U.S., a major hub for biotech innovation.
What is Moderna’s total equity as of June 2024?
Its total equity is $11.71 billion as of June 30, 2024.
Conclusion
Moderna remains a biotech powerhouse, and its financial performance reflects its resilience in a competitive market.
Share your thoughts and explore more detailed financial insights on our website at Ando Money.
